DORAVIRINE

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2014-2018
024620142018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Doravirine is a novel, highly potent, nonnucleoside reverse transcriptase inhibitor that is administered once daily and that is… (More)
  • table 2
Is this relevant?
2017
2017
INTRODUCTION Doravirine, a non-nucleoside reverse-transcriptase inhibitor in development for the treatment of patients with human… (More)
Is this relevant?
2017
2017
BACKGROUND Doravirine is a potent, once-daily, non-nucleoside reverse transcriptase inhibitor with a distinct resistance profile… (More)
  • table 1
  • table 3
  • table 4
  • table 2
  • table 4
Is this relevant?
2017
2017
INTRODUCTION Doravirine is a novel HIV-1 non-nucleoside reverse transcriptase inhibitor exhibiting a robust safety and efficacy… (More)
Is this relevant?
2016
2016
OBJECTIVE To assess the antiviral activity, pharmacokinetics, and safety of doravirine in nonnucleoside reverse transcriptase… (More)
Is this relevant?
2016
2016
Doravirine (DOR), which is currently in a phase 3 clinical trial, is a novel human immunodeficiency type 1 virus (HIV-1… (More)
Is this relevant?
2015
2015
The development of an efficient and robust process for the production of HIV NNRTI doravirine is described. The synthesis… (More)
Is this relevant?
2015
2015
Doravirine (DOR, formerly known as MK-1439) is a human immunodeficiency type 1 virus (HIV-1) nonnucleoside reverse transcriptase… (More)
Is this relevant?
2015
2015
BACKGROUND Doravirine is a novel non-nucleoside inhibitor of HIV-1 reverse transcriptase with potent activity against wild-type… (More)
  • table 1
  • table 3
  • table 2
  • table 4
  • figure 1
Is this relevant?
2014
2014
INTRODUCTION Doravirine (DOR) is an investigational NNRTI (aka MK-1439) that retains activity against common NNRTI-resistant… (More)
Is this relevant?